Internal Medicine, Medical Oncology · Naples, FL
NPI
1750370755
Since 2005
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
3530 Kraft Rd Ste 300
Naples, FL, 34105
Phone (239) 353-6636
Groups this clinician bills Medicare through
Medicare paid, 2024
$12.0M
695,013 services
Medicare patients, 2024
2,088
Average age 77
Drug cost, 2024
$9.4M
2,504 prescriptions
Company payments, 2025
$4,044
From 44 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Steven B Newman was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 110,670 times for 129 patients. In total Steven B Newman billed 695,013 services in 193 codes, and Medicare paid $12.0M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-02-04.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 110,670 | 129 | $0.28 | $30K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 68,200 | 61 | $44.45 | $3.0M |
| J9025 Injection, azacitidine, 1 mg | Office | 29,300 | 16 | $0.30 | $8,882 |
| Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Office | 27,600 | 22 | $0.22 | $5,951 |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 26,900 | 20 | $0.06 | $1,510 |
| J0185 Injection, aprepitant, 1 mg | Office | 24,180 | 55 | $1.33 | $32K |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 21,960 | 23 | $39.04 | $857K |
| J9299 Injection, nivolumab, 1 mg | Office | 20,080 | 12 | $24.59 | $494K |
| J9267 Injection, paclitaxel, 1 mg | Office | 18,067 | 23 | $0.08 | $1,426 |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 17,890 | 66 | $6.47 | $116K |
| J1756 Injection, iron sucrose, 1 mg | Office | 17,800 | 28 | $0.18 | $3,183 |
| Q5101 Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | Office | 16,920 | 12 | $0.27 | $4,512 |
| J0897 Injection, denosumab, 1 mg | Office | 16,680 | 138 | $20.37 | $340K |
| J1434 Injection, fosaprepitant (focinvez), 1 mg | Office | 15,150 | 27 | $2.31 | $35K |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 11,124 | 44 | $35.76 | $398K |
By year: 2022 $9.2M for 585,446 services; 2023 $10.9M for 708,108 services; 2024 $12.0M for 695,013 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 5,447 | 1,536 | $7.60 | $41K |
| 36415 Venipuncture Blood Collection | 5,178 | 1,583 | $8.65 | $45K |
| 85045 Blood Count | 517 | 289 | $3.90 | $2,018 |
| 81003 Clinical Chemistry | 165 | 114 | $2.19 | $361 |
| 85610 Clinical Chemistry | 14 | 11 | $4.20 | $58.8 |
Medicare prescription drug claims, 2024
In 2024, the drug Steven B Newman prescribed most often to Medicare patients was Ondansetron Odt (Ondansetron), with 139 prescriptions and refills. In total Steven B Newman wrote 2,504 Medicare prescriptions that cost $9.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ondansetron Odt Ondansetron | 139 | 142 | 94 | $2,410 |
| Xarelto Rivaroxaban | 133 | 249 | 38 | $135K |
| Letrozole Generic | 130 | 319 | 43 | $3,116 |
| Anastrozole Generic | 125 | 359 | 50 | $3,634 |
| Revlimid Lenalidomide | 125 | 125 | 18 | $2.3M |
| Acyclovir Generic | 81 | 174 | 27 | $1,553 |
| Hydroxyurea Generic | 71 | 199 | 24 | $2,958 |
| Jakafi Ruxolitinib Phosphate | 60 | 60 | Under 11 | $760K |
| Dexamethasone Generic | 58 | 94 | 39 | $1,557 |
| Zolpidem Tartrate Generic | 44 | 52 | 13 | $313 |
| Allopurinol Generic | 39 | 90 | 18 | $407 |
| Ibrance Palbociclib | 39 | 39 | Under 11 | $565K |
| Pomalyst Pomalidomide | 38 | 38 | Under 11 | $718K |
| Prednisone Generic | 37 | 40 | 27 | $342 |
| Alprazolam Generic | 36 | 44 | 16 | $361 |
Brand drugs: - claims; generic drugs: 1,666 claims; opioid claims: 116.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Steven B Newman $4,044 ($4,044 in general payments such as food, travel and fees) from 44 companies. The largest payer was Novartis Pharmaceuticals Corporation with $323.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 17 | $323 |
| Merck Sharp & Dohme LLC MRK | 10 | $282 |
| Pfizer Inc. PFE | 14 | $263 |
| Regeneron Healthcare Solutions, Inc. REGN | 10 | $256 |
| Gilead Sciences, Inc. GILD | 9 | $202 |
| Sobi, Inc SOBI.ST | 6 | $187 |
| Incyte Corporation INCY | 10 | $187 |
| GlaxoSmithKline, LLC. GSK | 10 | $178 |
| Janssen Biotech, Inc. JNJ | 9 | $174 |
| AstraZeneca Pharmaceuticals LP AZN | 7 | $170 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.